Bioceltix S.A. (WSE:BCX)

Bioceltix Statistics

Total Valuation

Bioceltix has a market cap or net worth of PLN 491.95 million. The enterprise value is 462.36 million.

Market Cap	491.95M
Enterprise Value	462.36M

Important Dates

The next estimated earnings date is Thursday, November 27, 2025.

Earnings Date	Nov 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Bioceltix has 4.92 million shares outstanding. The number of shares has increased by 19.13% in one year.

Current Share Class	4.92M
Shares Outstanding	4.92M
Shares Change (YoY)	+19.13%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	7.43%
Owned by Institutions (%)	22.84%
Float	3.83M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	15.67
P/TBV Ratio	15.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-33.04
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-32.69

Financial Position

The company has a current ratio of 8.06, with a Debt / Equity ratio of 0.01.

Current Ratio	8.06
Quick Ratio	7.84
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.03
Interest Coverage	-65.18

Financial Efficiency

Return on equity (ROE) is -36.70% and return on invested capital (ROIC) is -23.10%.

Return on Equity (ROE)	-36.70%
Return on Assets (ROA)	-20.29%
Return on Invested Capital (ROIC)	-23.10%
Return on Capital Employed (ROCE)	-44.93%
Revenue Per Employee	n/a
Profits Per Employee	-388,780
Employee Count	36
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Bioceltix has paid 31,119 in taxes.

Income Tax	31,119
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +29.74% in the last 52 weeks. The beta is 1.26, so Bioceltix's price volatility has been higher than the market average.

Beta (5Y)	1.26
52-Week Price Change	+29.74%
50-Day Moving Average	99.85
200-Day Moving Average	102.04
Relative Strength Index (RSI)	52.05
Average Volume (20 Days)	7,624

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-1.68M
Operating Income	-14.22M
Pretax Income	-13.96M
Net Income	-14.00M
EBITDA	-13.50M
EBIT	-14.22M
Earnings Per Share (EPS)	-2.84

Balance Sheet

The company has 30.05 million in cash and 455,145 in debt, giving a net cash position of 29.59 million or 6.01 per share.

Cash & Cash Equivalents	30.05M
Total Debt	455,145
Net Cash	29.59M
Net Cash Per Share	6.01
Equity (Book Value)	31.39M
Book Value Per Share	6.37
Working Capital	27.77M

Cash Flow

In the last 12 months, operating cash flow was -13.34 million and capital expenditures -804,959, giving a free cash flow of -14.14 million.

Operating Cash Flow	-13.34M
Capital Expenditures	-804,959
Free Cash Flow	-14.14M
FCF Per Share	-2.87

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Bioceltix does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.13%
Shareholder Yield	-19.13%
Earnings Yield	-2.84%
FCF Yield	-2.87%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2